Heparin Market

Market Overview

The global heparin market had a revenue share of USD 7,025 million in 2021, expected to project to USD 11,891 million at a CAGR of 6.8% during the forecast period. 

Heparin is an anticoagulant medicine and a glycosaminoglycan produced naturally by basophils and mast cells in all mammals. It is used to prevent the formation of blood clots resulting from certain medical conditions or procedures. It treats various medical conditions, including acute coronary syndrome, deep-vein thrombosis, pulmonary embolism, and atrial fibrillation. It is also utilized during cardiac surgery for cardiopulmonary bypass and hemofiltration. It is also administered during major orthopedic procedures, like hip and knee replacement. Recent advances in heparin research to create ultra-low molecular weight heparin for use in chemotherapy have created new opportunities in the heparin market.

Heparin treats various medical conditions, including acute coronary syndrome, deep vein thrombosis, pulmonary embolism, atrial fibrillation, cardiopulmonary bypass, and hemofiltration during heart surgery. Hip and knee replacements and other major orthopedic procedures can be administered with this device. The increasing incidence of venous thrombosis drives the growth of the global market due to underlying factors such as cardiovascular disease. In addition, the use of heparin in various surgical procedures, such as orthopedic and heart surgeries, and the rise in the number of patients undergoing such procedures contribute to the market expansion. However, numerous adverse side effects of heparin, such as heparin-induced thrombocytopenia, inhibit the market's expansion. In addition, because heparin is derived from animal sources, it presents a significant safety and supply issue, further restricting market expansion.

Market Dynamics

Global Heparin Market Drivers

Increased Occurrence of Venous Thromboembolism and Cardiovascular Disorders to Favor Market Growth

The growing prevalence of coagulation disorders, like venous thromboembolism (VTE), which contains both deep vein thrombosis and pulmonary embolism, boosts the demand for the heparin market. VTE, which encompasses both deep vein thrombosis and pulmonary embolism, is responsible for the death of approximately 1.2 million people annually worldwide. In addition, VTE is Europe's leading cause of death, surpassing AIDS, breast and prostate cancer, and traffic accidents combined. In addition, an increase in hypertension cases due to an unhealthy lifestyle drives the expansion of the global market.

In addition, the increased rate of cardiovascular diseases, such as heart attacks and strokes, will create market opportunities. As per the American Heart Association (AHA), Heart Disease and Stroke Statistics, atrial fibrillation affected 5.3 million Americans in 2019. Increasing patient demand for heparin may have a substantial impact on the market.

Growing Geriatric Population to Positively Share Industry Outlook

Venous thromboembolism (VTE) is prevalent among the elderly, but it can affect people of any age. The incidence of various illnesses, such as heart failure, which can result in thrombosis, is more significant in the elderly than in the young. Congestive heart failure is significantly more prevalent in the elderly, with 85% of heart failure patients being older than 65. Atrial fibrillation is three times more prevalent in individuals over 80 than those under 65. Such incidents increase the risk of pulmonary embolism, particularly in elderly individuals. Consequently, the increase in the geriatric population boosts the demand for heparin to treat disorders and the growth of the heparin market.

Global Heparin Market Restraints

Heparin Side Effects to Hinder Market Growth

Heparin's side effects are the primary factors restraining the market's growth. Bleeding is the most common adverse effect of heparin. Heparin can cause spontaneous bleeding from open wounds or surgical sites, the intestines and stomach, the ovaries and uterus, and the mouth and gums. In addition, heparin can cause heparin-induced thrombocytopenia (HIT), which increases the risk of bleeding by causing the immune system to produce antibodies against the body's platelets. Consequently, the adverse effects associated with heparin may impede market growth over the forecast period.

Global Heparin Market Opportunities

Synthetic and Semi-Synthetic Heparin Mimetics Availability in the Market

Synthesized or partly synthesized heparin mimetics are highly sulfated, structurally distinct analogs of glycosaminoglycans. Frequently, these mimics are engineered to enhance the potency and binding selectivity for specific proteins involved in disease manifestations. Thrombosis and coagulation are three of the most prevalent clinical applications of heparin mimetics. The abundance of synthetic and semi-synthetic heparin mimetics that aid in the treatment of various cancers, coagulation, and inflammatory diseases is driving the growth of the  market and significantly increasing product adoption.

Regional Analysis

The regional segmentation of the global heparin market includes North America, Europe, Asia-Pacific, and LAMEA.

Why is Asia-Pacific and Europe Projected to be the Most Lucrative Market During the Assessment Period?

Europe will have the largest share in the market, advancing at a CAGR of 7% during the forecast period. Due to the increasing geriatric population and prevalence of long-term acute myocardial infarction survivors, the region will hold a significant share of the regional market (AMI). Additionally, the adoption of technologically advanced products in the region, the presence of developed infrastructure in the healthcare industry, and investments in research and development for the heparin mechanism all contribute to the market growth in this region.

In addition, the increase in the geriatric population base, the increase in the number of surgical procedures, including knee replacement, hip surgeries, and cardiovascular surgeries, among others, and the rising prevalence and incidence of VTE in Germany have propelled the growth and intake of heparin-based formulations over the past few years. According to statistics published by the International Society on Thrombosis and Haemostasis, Inc., nearly 10 million cases of VTE are reported annually worldwide, with approximately 544,000 VTE-related deaths occurring annually in Europe. In addition, the adoption of technologically advanced products within the region contributes to the expansion of the market.

Asia-Pacific will have the second-largest share of USD 3,178 million, growing at a CAGR of 8% during the forecast period. During the forecast period, the Asia-Pacific market is anticipated to expand significantly due to growing healthcare infrastructure and escalating efforts by private & public organizations. These factors are projected to fuel the heparin market's growth in developing Asia-Pacific countries. In addition, a larger patient pool for cardiovascular diseases and an aging population contribute to the market's expansion.

The increasing patient population and the growing prevalence rate of cancer and other chronic diseases or coronary heart diseases, myocardial infarction, and stroke among the regional population have increased demand for heparin products and contributed to the region's market growth. In addition, Asia-Pacific is anticipated to experience the fastest market growth during the forecast period due to its rapidly growing healthcare infrastructure, untapped resources, economic growth, and increasing initiatives by private and public organizations.

Segmental Analysis

The global heparin market is bifurcated based on product, application, distribution channel, and region.

By Product

Based on the product, the fragments include unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). 

Low molecular weight heparin (LMWH) will have the largest market share during the forecast period advancing at a CAGR of 7%. Anticoagulant LMWH (low molecular weight heparin) is used to thin the blood. LMWH comprises smaller heparin fragments derived from unfractionated heparin (UFH) via controlled enzymatic depolymerization. Numerous advantages of low molecular weight heparin over unfractionated heparin, such as more prolonged and more predictable activity than UFH and easy self-administration at home via subcutaneous injection, which reduces or eliminates hospital stays, are expected to drive the growth of this segment over the forecast period. Moreover, the  market is expected to grow as government healthcare regulatory bodies become more concerned with developing and providing efficient and cost-effective low molecular weight heparin molecule products.

Ultra-low molecular weight heparin will have the second-largest market share. Ultra-low molecular weight heparin (ULMWH) is a form of heparin that can be used to prevent blood clot formation and thin the blood. This segment's growth is primarily driven by the rising incidence of venous thromboembolism (VTE) in sick people and the different applications of ULMWH in diagnosing VTE, pregnancy complications, and atrial fibrillation.

By Application

Based on application, the fragments include venous thromboembolism, coronary artery disease, atrial fibrillation, and others.

Venous thromboembolism is most likely to hold the largest market share growing at a CAGR of 7% during the forecast period. Blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) are all synonyms for venous thromboembolism. VTE is a form of blood clot that originates in a vein. It is the third most prevalent vascular diagnosis after a heart attack and stroke. DVT can occur in the veins of the arm or other locations. A pulmonary embolism happens when a DVT clot breaks away from a vein wall, travels to the lungs, and then obstructs some or all blood flow to the lungs. It is more likely that blood clots originating in the thigh will break off and travel to the lungs than blood clots originating in the lower leg or elsewhere in the body.

Coronary artery disease will hold the second-largest share. Coronary artery disease (CAD) is also known as coronary heart disease (CHD), ischemic heart disease (IHD), and heart disease. Coronary artery disease happens when the major blood vessels that supply the heart with blood become damaged or infected. High blood pressure, smoking, diabetes, inactivity, obesity, high blood cholesterol, a poor diet, depression, and excessive alcohol consumption are all risk factors for coronary artery disease.

By Distribution Channels

Based on distribution channels, the fragments include drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. 

Hospital pharmacies will hold the largest market share growing at a CAGR of 6.7% during the forecast period. Hospital pharmacies are specialized branches of pharmacy that are located within hospitals. Preparing, storing, compounding, and dispensing medications and medical devices, as well as advising healthcare professionals and patients on their safe and effective use, are included. The hospital pharmacies segment will have the largest market share due to patients' confidence in hospitals offering high-quality services and easy access to medications. Moreover, the rise in hospital admissions for operations and treatments also contributes to the expansion of this market segment.

Drug stores & retail pharmacies will have the second-largest share in 2030. The business of a drug store and retail pharmacy includes the sale of cosmetics, first-aid supplies, prescription medications, and non - prescribed medications or over-the-counter products. In addition to providing general health information, the pharmacist may be responsible for patient counseling and education, drug safety management, prescription analysis, tracking, and reconciliation, as well as identifying and controlling specific respiratory risk factors. As a result, the market is anticipated to expand substantially during the forecast period.

Recent Developments

• In 2022, B. Braun Holding GmbH & Co. KG acquired Intermedt Medizin & Technik GmbH.
• In 2022, Dr. Reddy's Laboratories Ltd. announced the launch of Methylprednisolone Sodium Succinate for Injection USP in the US market.
• In 2022, Dr. Reddy's Laboratories Ltd. and MediCane Health Inc. announced the launch of therapeutic cannabis in Germany.
• In 2022, Fresenius SE & Co KGaA announced the acquisition of Ivenix, Inc.